High alert medications off the radar: A systematic review

Objective: To identify new drugs that present an increased risk of causing significant damage to critically ill patients due to failure in the administration process. Method: The systematic literature review was conducted in the PubMed, Lilacs, Scopus, Web of Science and gray literature. The year in...

Full description

Saved in:
Bibliographic Details
Main Authors: Michelle Santos Menezes, Fernanda Valença-Feitosa, Aline Santana Góes, Millena Rakel dos Santos, Laila Santana Silva, Sylmara Nayara Pereira dos Santos, Divaldo Pereira de Lyra Jr, Alfredo Dias de Oliveira Filho
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Exploratory Research in Clinical and Social Pharmacy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667276624001483
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To identify new drugs that present an increased risk of causing significant damage to critically ill patients due to failure in the administration process. Method: The systematic literature review was conducted in the PubMed, Lilacs, Scopus, Web of Science and gray literature. The year in which the study was conducted was not restricted. Results: The initial search in the databases identified 1477 studies. Fifty manuscripts were selected for evaluation of the full text, at the end of which seven articles were included in this systematic review. As for the characteristic of medication errors, the highest frequency occurred in the administration and prescription phases. In all included studies, incidents with drugs that led to damage were observed. The drugs that are not included in the official lists as High Alert Medications (HAM) that presented an increased risk of causing damage due to medication errors found were: risperidone and piperacycline + tazobactan, in addition to the Infectious Agent class. Conclusion: The results revealed that in fact there are drugs not listed as HAM that, when used in errors, promote greater risks of generating damage in critically ill patients. These described drugs should be considered for inclusion in future official lists of HAM.
ISSN:2667-2766